From AGM presentation 8/11/2023
Phase I/II Clinical Trial – Treatment of Burn Wound Infections
• Stage 1 Complete
• Patients treated with R327 showed good indications of safety and tolerability
• No serious adverse events reported among patients
• Clinical investigators are preparing a new protocol of next stage
• Stage 2 clinical trial expected to be a randomised ‘head-to-head’ in patients with infected
burn wounds, where R327G treatment is compared to existing treatment standard of care.
Burns wound trial seems to have gone very quiet with no mention in the quarterly report 30/1/2024
I requested information on the Phase 1 readout (expected 4th quarter 2023) last week and so far no reply.
Does anyone have information on the Burn wound trial stage I and proposed stage II ?
- Forums
- ASX - By Stock
- Burns wound update
RCE
recce pharmaceuticals ltd
Add to My Watchlist
21.9%
!
44.5¢

From AGM presentation 8/11/2023 Phase I/II Clinical Trial –...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
44.5¢ |
Change
0.080(21.9%) |
Mkt cap ! $128.6M |
Open | High | Low | Value | Volume |
37.5¢ | 44.5¢ | 37.5¢ | $191.2K | 477.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 12222 | 44.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
45.0¢ | 10976 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 12222 | 0.440 |
2 | 8000 | 0.425 |
1 | 50000 | 0.420 |
1 | 4175 | 0.415 |
2 | 69894 | 0.400 |
Price($) | Vol. | No. |
---|---|---|
0.450 | 10976 | 2 |
0.460 | 14304 | 2 |
0.470 | 100000 | 1 |
0.490 | 8000 | 1 |
0.500 | 13381 | 3 |
Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
Featured News
RCE (ASX) Chart |
The Watchlist
P.HOTC
HotCopper
Frazer Bourchier, Director, President and CEO
Frazer Bourchier
Director, President and CEO
SPONSORED BY The Market Online